What is HC Wainwright’s Forecast for TRVI Q1 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for Trevi Therapeutics in a research report issued on Wednesday, March 18th. HC Wainwright analyst B. Folkes forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS and FY2030 earnings at $0.79 EPS.

A number of other equities research analysts have also recently issued reports on TRVI. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Morgan Stanley dropped their target price on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday. JonesTrading cut their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday. D. Boral Capital reiterated a “buy” rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC boosted their price objective on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $21.60.

Trevi Therapeutics Trading Down 0.8%

Shares of TRVI stock opened at $10.61 on Thursday. The firm’s 50 day moving average is $11.13 and its 200 day moving average is $10.95. The stock has a market capitalization of $1.36 billion, a P/E ratio of -33.16 and a beta of 0.94. Trevi Therapeutics has a 12 month low of $4.85 and a 12 month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRVI. Russell Investments Group Ltd. grew its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Trevi Therapeutics during the fourth quarter valued at $50,000. Strs Ohio bought a new stake in Trevi Therapeutics during the first quarter valued at $52,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Trevi Therapeutics during the second quarter worth about $56,000. 95.76% of the stock is owned by institutional investors.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi beat Q4 2025 EPS expectations (reported -$0.06 vs. about -$0.096), providing near-term fundamental support and likely driving early buying interest after the print. Q4 2025 earnings transcript
• Positive Sentiment: Needham raised its price target to $24, signaling continued analyst conviction and a sizable implied upside from current levels. Needham raises PT to $24
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating, adding to the roster of buy-side endorsements that may support demand in the shares. D. Boral Capital reaffirms Buy
• Positive Sentiment: JonesTrading trimmed its price target slightly (from $25 to $24) but kept a Buy rating — the change is modest and leaves a large upside implied by street targets. JonesTrading PT update
• Neutral Sentiment: Full earnings-call transcript and coverage are available for investors reviewing management commentary and execution details; useful for gauging guidance and pipeline progress but not new news by itself. Earnings transcript
• Neutral Sentiment: Analyst write-ups (e.g., Globe and Mail summary) provide context and viewpoints but do not change fundamentals immediately. Analyst insights
• Negative Sentiment: HC Wainwright cut multi-year EPS forecasts across FY2026–FY2029 (notably downgrading several yearly EPS projections) while maintaining a Buy rating and a $21 target — the lower earnings trajectory may temper enthusiasm around near-term profitability and valuation. HC Wainwright estimate revisions
• Negative Sentiment: Morgan Stanley signaled lower expectations for TRVI, adding downward pressure from a major institutional voice and contributing to intraday weakness. Morgan Stanley lowers expectations

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.